Enterome selected as one of the most promising therapeutic biotechs, highlighting the potential of its innovative OncoMimics™ immunotherapies to transform cancer therapy

Paris, France – June 15, 2023

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, announces that it has been selected for the prestigious French Tech 2030 program. Enterome was selected as one of the most innovative and promising therapeutic biotechs in France, having developed a unique platform and highly innovative approach to treating cancer and inflammatory diseases.

Enterome will benefit from financial and non-financial support for one year which will support the clinical advancement of its innovative OncoMimics™ immunotherapies targeting solid and liquid tumors that were generated by its highly productive and pioneering Mimicry platform.

The French Tech 2030 is a program, steered by the General Secretariat for Investment and supported by Mission French Tech and Bpifrance, with a view to strengthen France’s industrial and technological sectors, including biotechnology and healthcare. As part of the program, 125 emerging players are selected according to France 2030 objectives; to demonstrate capabilities to accelerate the development and production of 20 biomedicines against cancers and chronic diseases, and the creation of tomorrow’s medical devices.

Access to the programs strategic insights and international network will play an important role in the Company’s development and its mission to establish OncoMimics™ immunotherapies as potential breakthrough drugs for treating aggressive forms of cancer. Earlier this year, the Company announced positive clinical results from its ongoing ROSALIE trial with EO2401 in recurrent glioblastoma and from its SIDNEY trial with EO2463 in Non-Hodgkin Lymphoma. In addition, OncoMimics™ candidates, EO2040 in colorectal cancer with ctDNA-defined, minimal residual disease, and EO4010 for third-line colorectal cancer are planned to enter clinical trials in 2023.

Pierre Belichard, Chief Executive Officer at Enterome said “We are honored to have been selected by the French Tech 2030 program, which recognizes the potential of our Mimicry approach and the ability of OncoMimics™-based immunotherapies to treat aggressive forms of cancer that resist today’s most effective treatments in broad patient populations. A great thanks to the entire team at Enterome for this win, which wouldn’t have been possible without their hard work and relentless pursuit for scientific excellence as well as their unwavering dedication to help patients in need of therapeutic solutions.”

The final selection was made by the programs committee, which is chaired by Bruno Bonnell, General Secretary for Investment in charge of ‘France 2030’, and comprises of representatives from the Direction Générale des Entreprises (the General Directorate for Enterprise), the Direction Générale de la Recherche et de l’Innovation (the General Directorate for Research and Innovation), the Agence de l’Innovation de Défense (the Defense Innovation Agency), the Agence de l’Innovation en Santé (the Health Innovation Agency) and the Commissariat Général au Développement Durable (General Commissariat for Sustainable Development) and Bpifrance.

 

***

Contacts

ENTEROME	MEDIA RELATIONS
Guillaume Bayre Head of External Communications Tel; +33 (0)1 76 21 58 15 communication@enterome.com	Sylvie Berrebi / Mark Swallow / David Dible MEDiSTRAVA Consulting Tel. +44 (0) 203 928 6900 enterome@medistrava.com

 

About Enterome

Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.

Enterome’s first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines.

The company’s two pipelines of drug candidates include:

• OncoMimics™ peptides, a pipeline of peptide-based immunotherapies. Lead candidate, EO2401, is in Phase 2 clinical trials in patients with glioblastoma and adrenal tumors and has demonstrated clinical proof of concept. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin lymphomas, and has demonstrated a good safety profile with first signs of efficacy. EO2040, a new immune therapy, is expected to start a Phase 2 trial in 2023 in patients suffering from colorectal cancer with ctDNA-defined, minimal residual disease. EO4010 is in development for third-line colorectal cancer and targeted to enter clinical trials in 2023.
• EndoMimics™ peptides, a pipeline of next generation bioactives acting like human hormones or cytokines, are being developed in collaboration with Nestlé Health Science, for food allergies and inflammatory bowel disease (IBD). Lead candidate, EB1010, expected to enter the clinic in 2024, is a potent local inducer of IL-10, designed to improve therapeutic outcomes for patients with IBD.

Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €116 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.

 

For more information, please visit the company’s website at: www.enterome.com